Hormone combo around surgery may redefine care for high-risk prostate cancer
A phase 3 PROTEUS trial shows that administering two hormone therapies both before and after prostate cancer surgery improves outcomes versus a single hormone therapy in high-risk, early-stage patients, a result that some doctors see as paving the way for a potential new standard of care.